Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Neoplasm Metastasis 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hodgkin Disease 3Endometrial Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Mantle-Cell 2Thyroid cancer, follicular 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Recurrence 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Metastatic Castration-resistant Prostate Cancer 1

Interventions

trametinib 1spartalizumab 1dabrafenib 1copanlisib 1Vemurafenib 1Thyroidectomy 1Lymph Node Excision 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thyroid cancer, follicular × copanlisib × Clear all
NCT04462471 2025-09-08

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
8 enrolled 8 charts
EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡